An overview of pharmaceutical cocrystals as intellectual property.

  title={An overview of pharmaceutical cocrystals as intellectual property.},
  author={Andrew Vincent Trask},
  journal={Molecular pharmaceutics},
  volume={4 3},
  • A. V. Trask
  • Published 4 May 2007
  • Materials Science
  • Molecular pharmaceutics
This review article focuses on the interaction among certain scientific, legal, and regulatory aspects of pharmaceutical crystal forms. The article offers an analysis of pharmaceutical cocrystals as patentable inventions by drawing upon recent scientific developments in the field. Several potential commercial advantages of pharmaceutical cocrystals are highlighted, and a number of recent court decisions involving salient issues are summarized. The article provides an outlook on how the… 

The role of cocrystals in pharmaceutical science.


As in recent years, due to the pervasiveness of poorly soluble APIs that demonstrates poor and erratic bioavailability, pharmaceutical cocrystal’s applicability to tailor the physicochemical

Pharmaceutical Cocrystal Drug Products: An Outlook on Product Development.

The role of co-crystals in pharmaceutical design.

  • J. Steed
  • Materials Science
    Trends in pharmacological sciences
  • 2013

Pharmaceutical Cocrystals: Regulatory and Strategic Aspects, Design and Development.

The design, synthesis, strategic aspects and characteristics of cocrystals along perspectives on its regulatory and intellectual property considerations are dealt with.

A Review about Regulatory Status and Recent Patents of Pharmaceutical Co-Crystals

Whether co-crystals fulfil the requirements for the grant of a patent or not and how cocrystals are going to affect the present scenario of pharmaceuticals are highlighted.

Cocrystal engineering of pharmaceutical solids: therapeutic potential and challenges

An overview of pharmaceutical cocrystal production and its potential in reviving problematic properties of drugs in different dosage forms and the challenges and future outlook of its translational development are discussed.

Recent Advances on the Biological Study of Pharmaceutical Cocrystals

Although pharmaceutical cocrystals face some challenges in clarifying the characteristics of metabolism and distribution, revealing potential pharmacological mechanism, and evaluating safety, cocrystal engineering is still considered a green and promising approach to developing valuable new drugs.

Pharmaceutical Co-Crystals: A New Paradigm of Crystal Engineering

A review on pharmaceutical co-crystals, nutraceutical co-crystals and pharmaceutical co-crystal polymorphs depicting their relevance both in academia and pharmaceutical industry because of their

Engineering and manufacturing of pharmaceutical co-crystals: a review of solvent-free manufacturing technologies.

Design and synthesis of pharmaceutical cocrystals have received great interest and significant efforts have been directed towards computational screening, cocrystal manufacturing in a continuous manner and real-time monitoring for quality purposes by using various analytical tools.



Pharmaceutical Cocrystals: An Emerging Approach to Physical Property Enhancement

Pharmaceutical cocrystals are crystalline molecular complexes containing therapeutic molecules. They represent an emerging class of pharmaceutical materials offering the prospect of optimized

Crystal engineering of the composition of pharmaceutical phases. Do pharmaceutical co-crystals represent a new path to improved medicines?

It has become clear that a wide array of multiple component pharmaceutical phases, so called pharmaceutical co-crystals, can be rationally designed using crystal engineering, and the strategy affords new intellectual property and enhanced properties for pharmaceutical substances.

Development of a pharmaceutical cocrystal of a monophosphate salt with phosphoric acid.

We report the first case of a pharmaceutical cocrystal formed between an inorganic acid and an active pharmaceutical ingredient (API), which enabled us to develop a stable crystalline and

Pharmaceutical co-crystals.

This review addresses how crystal engineering has been applied to active pharmaceutical ingredients, API's, with emphasis upon how pharmaceutical co-crystals, a long known but little explored alternative to the four traditionally known forms of API, can be generated in a rational fashion.

Crystal structures of drugs: advances in determination, prediction and engineering

The different crystal forms of pharmaceuticals, the challenges that they present and recent advances in crystal structure determination are reviewed, and computational approaches for predicting crystal properties are discussed.

Use of a Glutaric Acid Cocrystal to Improve Oral Bioavailability of a Low Solubility API

Use of the cocrystal increased the aqueous dissolution rate by 18 times as compared to the homomeric crystalline form of the drug and showed that it is unique regarding thermal, spectroscopic, X-ray, and dissolution properties.

Crystal engineering of novel cocrystals of a triazole drug with 1,4-dicarboxylic acids.

The results suggest that cocrystals of drug molecules have the possibility of achieving the higher oral bioavailability common for amorphous forms of water-insoluble drugs while maintaining the long-term chemical and physical stability that crystal forms provide.

Carboxamide-pyridine N-oxide heterosynthon for crystal engineering and pharmaceutical cocrystals.

The novel carboxamide-pyridine N-oxide synthon is shown to assemble isonicotinamide N- oxide in a triple helix architecture and the same heterosynthon is exploited to synthesize cocrystals of barbiturate drugs with 4,4'-bipyridineN,N'-dioxide.

Prediction and observation of isostructurality induced by solvent incorporation in multicomponent crystals.

The crystal structures of two pharmaceutical molecules-carbamazepine and its 10,11-dihydro derivative-with acetic acid have been successfully predicted by computational methods. While the crystalline